Diabetes Mellitus Clinical Trial
Official title:
Diabetes Quality Improvement Program on Diabetes Case Management Program 2001
In order to assess more completely the levels of diabetes care delivered in Taiwan, we now
have nationally standardized performance measures that can evaluate quality of diabetes care
accurately and reliably. These performance measures were seriously reviewed and discussed in
the aspects of their practicability, feasibility and compliancy, through a series of
nation-wide consensus meetings by a number of multidisciplinary professionals of Taiwan
Diabetes Care Teams ( TDCTs ), before delivering into the clinical settings ( 10 ).
Conceptually, these measures will enhance uptake of research into practice and may
ultimately improve diabetes care and clinical outcomes. Along with the serial developments
mentioned above, the BNHI ( the sole healthcare insurance organization in Taiwan ) has been
fully involved, from the very beginning, in the formation and development of these
performance measures which have totally been included in the development of the Diabetes
Case Management Program ( DCMP ) 2001 later on. The DCMP 2001 is a unique program that has
been delivered into the nation-wide clinical practices since Dec. 2001 in Taiwan. It has
linked the quality of diabetes care to the monthly income ( reimbursed from BNHI ) of the
registered clinical diabetes educators ( i.e., physicians, nurses and dietitians ) for
enhancing and assuring the complete implementation of these performance measures in diabetes
care. It has been recognized that a consensus on measures at national level could provide a
method for assessing care within and across healthcare settings while providing a meaningful
mechanism for quality improvement. In this proposal, we are going to develop the Diabetes
Quality Improvement Program ( DQIP ) based on the DCMP 2001 in Taiwan.
Initially, we are going to establish the continuous diabetes quality monitoring system and
then to evaluate the (1) the lifestyles and eating habits and dietary compositions in type 2
diabetes mellitus (2)The relationships between lifestyles and eating habits and dietary
compositions in diabesity.
Diabetes is now a global epidemic; it is the fourth or fifth leading cause of death in most
developed and newly industrialized countries. People with diabetes mean a long-term
condition that deserves effective and efficient care throughout their lives. Complications
caused by diabetes, such as coronary artery and peripheral vascular diseases, stroke,
diabetic neuropathy, amputations, renal failure and blindness are resulting in increasing
disability, reduced life expectancy and, even more apprehensive, enormous healthcare related
expense for virtually every society ( 1, 2 ). Diabetes is certainly one of the most
challenging health issues in the 21st century.
The most recent epidemiological data suggested that the diabetes population in Taiwan has
reached one million ( 3 ). People with diabetes using the healthcare insurance regularly for
their diabetes care, however, were only 60 % of total diabetes population. Nevertheless,
this 60 % of Taiwan diabetes population had already consumed more than 12 % of total
national annual healthcare expenditure in taking care of them. In fact, this diabetes
population was merely one- forties of Taiwan population as a whole. Even the worst thing was
that more than 60 % of the whole yearly healthcare budget for taking care of diabetes had
gone into the treatment of diabetes-related complications ( 4,5 ). We have recently learned
from some of the prevention trials, such as the Diabetes Control and Complications Trial (
DCCT ) in type 1 diabetes and the United Kingdom Prospective Diabetes Study ( UKPDS ) in
type 2 diabetes, that effective and adequate performance of metabolic and blood pressure
control in patients with diabetes would be able to delay or even prevent the
diabetes-related complications ( 6-8 ). These interventions, if broadly implemented, would
help to improve the living quality of diabetes patients, and as well as to consequently make
the biggest gain out of healthcare expenditure ( 9 ). In order to assess more completely the
levels of diabetes care delivered in Taiwan, we now have nationally standardized performance
measures that can evaluate quality of diabetes care accurately and reliably. These
performance measures were seriously reviewed and discussed in the aspects of their
practicability, feasibility and compliancy, through a series of nation-wide consensus
meetings by a number of multidisciplinary professionals of Taiwan Diabetes Care Teams (
TDCTs ), before delivering into the clinical settings ( 10 ).
Conceptually, these measures will enhance uptake of research into practice and may
ultimately improve diabetes care and clinical outcomes. Along with the serial developments
mentioned above, the BNHI ( the sole healthcare insurance organization in Taiwan ) has been
fully involved, from the very beginning, in the formation and development of these
performance measures which have totally been included in the development of the Diabetes
Case Management Program ( DCMP ) 2001 later on. The DCMP 2001 is a unique program that has
been delivered into the nation-wide clinical practices since Dec. 2001 in Taiwan. It has
linked the quality of diabetes care to the monthly income ( reimbursed from BNHI ) of the
registered clinical diabetes educators ( i.e., physicians, nurses and dietitians ) for
enhancing and assuring the complete implementation of these performance measures in diabetes
care. It has been recognized that a consensus on measures at national level could provide a
method for assessing care within and across healthcare settings while providing a meaningful
mechanism for quality improvement. In this proposal, we are going to develop the Diabetes
Quality Improvement Program ( DQIP ) based on the DCMP 2001 in Taiwan.
Initially, we are going to establish the continuous diabetes quality monitoring system and
then to evaluate the (1) the lifestyles and eating habits and dietary compositions in type 2
diabetes mellitus (2)The relationships between lifestyles and eating habits and dietary
compositions in diabesity.
;
Observational Model: Defined Population, Time Perspective: Longitudinal
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
| Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
| Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
| Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
| Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
| Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
| Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
| Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
| Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
| Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
| Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
| Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
| Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
| Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
| Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |